Buradasınız

Anasayfa » Content

Multipl miyelomlu bir hastada başarısız kanal tedavisine bağlı olarak gelişen mandibular osteomiyelit

Mandibular osteomyelitis developing due to a failed root canal treatment in a patient with multiple myeloma

Journal Name:

  • Gülhane Tıp Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
Hundreds of patients with bisphosphonate-associated osteonecrosis have been reported worldwide, and in several of those individuals, evidence of osteomyelitis has been found. However, to our knowledge, osteomyelitis without osteonecrosis has not been reported in patients treated with bisphosphonates. This case report describes a patient with multiple myeloma in remission who was treated with bisphosphonates and osteomyelitis developed due to insufficient root canal treatment. The patient had bone marrow transplantation after the elimination of ongoing inflammation.
Bookmark/Search this post with
Abstract (Original Language): 
Dünyada bifosfonat kullanımana bağlı olarak osteonekroz gelişen yüzlerce hasta bildirilmiştir ve bunların pek çoğunda osteomiyelit bulgusuna rastlanmamıştır. Ancak bildiğimiz kadarıyla bifosfonat kullanan hastalarda osteonekroz olmaksızın osteomiyelit gelişimi bildirilmemiştir. Bu vaka raporunda, bifosfonat ile tedavi edilip remisyon dönemine girmiş multipl miyelomlu bir hastada yetersiz yapılan kanal tedavisine bağlı olarak osteonekroz olmaksızın gelişen mandibular osteomiyelit sunulmaktadır. İnflamasyonun tedavi edilmesinden sonra hastaya kemik iliği transplantasyonu uygulanmıştır.
FULL TEXT (PDF): 
PDF icon arastirmax-multipl-miyelomlu-bir-hastada-basarisiz-kanal-tedavisine-bagli-olarak-gelisen-mandibular-osteomiyelit.pdf
  • 4
264-267
  • English

REFERENCES

References: 

1. Barlogie B, Shaughnessy J, Munshi N, Epstein J. Plasma
cell myeloma. In: Beutler E, Lichtman MA, Coller BS,
Kipps TJ, Seligsohn U (eds). Williams Hematology. 6th
ed. McGraw-Hill, 2001: 1279.
2. Tricot G. Multiple myeloma and other plasma cell disorders. In: Hoffman R, Benz EJ, Shattil SJ (eds).
Hematology: Basic Principles and Practice. 4th ed.
Philadelphia: Churchill Livingstone, 2004: 1501.
3. Lenhoff S, Hjorth M, Holmberg E, et al. Nordic
Myeloma Study Group. Impact on survival of high-dose
therapy with autologous stem cell support in patients
younger than 60 years with newly diagnosed multiple
myeloma: a population-based study. Blood 2000; 95: 7-
11.
4. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of
action. Review. J Clin Invest 1996; 97: 2692-2696.
5. Marx RE, Sawatari Y, Fortin M, Broumand V.
Bisphosphonate-induced exposed bone (osteonecrosis/
osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:
1567-1575.
6. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL.
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg
2004; 62: 527-534.
7. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw
osteonecrosis in association with cancer chemotherapy:
series of 10 cases. J Oral Pathol Med 2005; 34: 120-123.
8. Migliorati CA. Bisphosphonates and oral cavity avascular
bone necrosis. J Clin Oncol 2003; 21: 4253-4254.
9. Berenson JR. New advances in the biology and treatment
of myeloma bone disease. Semin Hematol 2001; 38: 15-
20.
10. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the
jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580-8587.
11. Migliorati CA, Schubert MM, Peterson DE, Seneda LM.
Bisphosphonate-associated osteonecrosis of mandibular
and maxillary bone: an emerging oral complication of
supportive cancer therapy. Cancer 2005; 104: 83-93.
12. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the
jaw in multiple myeloma patients: clinical features and
risk factors. J Clin Oncol 2006; 24: 945-952.
13. Paradisi F, Corti G, Cinelli R. Infections in multiple
myeloma. Infect Dis Clin North Am 2001; 15: 373-384.
14. Thakkar SG, Isada C, Smith J, et al. Jaw complications
associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol 2006; 23: 51-56.
15. Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R,
Mueller PC, Gundlach KK. Does avascular necrosis of the
jaws in cancer patients only occur following treatment
with bisphosphonates? J Craniomaxillofac Surg 2005; 33:
395-403.
16. Talamo G, Angtuaco E, Walker RC, et al. Avascular
necrosis of femoral and/or humeral heads in multiple
myeloma: results of a prospective study of patients treated
with dexamethasone-based regimens and high-dose
chemotherapy. J Clin Oncol 2005; 23: 5217-5223.

Thank you for copying data from http://www.arastirmax.com